ClinicalTrials.gg
CompletedNCT07343310Updated Jan 20, 2026

A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP

A Phase 1 interventional study of KINE-101 in CIDP - Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Kine Sciences Co., Ltd.. Completed at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Kine Sciences Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Aug 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating polyneuropathy (CIDP). On Day 1, subjects receive a single IV dose of KINE-101 at the assigned cohort level and are discharged on Day 3, approximately 48 hours after investigational product (IP) administration, once all required in-clinic assessments have been completed. Safety assessments (including dose-limiting toxicities [DLTs], adverse events, clinical laboratory tests, vital signs, physical examinations, and 12-lead ECGs), exploratory efficacy evaluations, and PK/PD assessments are conducted through Day 28 in accordance with the schedule of assessments.

Exploratory efficacy assessments through Day 28 include changes from baseline in the following clinical measures: Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Medical Research Council (MRC) total sum score, Inflammatory Rasch-Built Overall Disability Scale (I-RODS), Timed Up-and-Go (TUG) test, mean grip strength, and the Overall Neuropathy Limitations Scale (ONLS).

Pharmacodynamic (PD) assessments include immunophenotyping of CD4+ T-cell subsets (CD4, CD25, FOXP3, CD39, CD69, CTLA-4, LAG-3, TNFR2, TIGIT, CCR5, and CXCR3); measurement of serum cytokines and immunoglobulins (IgM, IgG, IL-2, IL-6, IL-10, IL-17, IFN-γ, MCP-1, and TGF-β); evaluation of autoantibody and complement markers (antinuclear antibodies, anti-SM, anti-RNP, anti-SSA, anti-double-stranded DNA antibodies, and complement C4); and additional laboratory parameters related to systemic inflammation.

Dose escalation follows a standard 3+3 design based on review of safety, including DLTs, in the preceding cohort. Three KINE-101 dose cohorts are planned: Cohort 1 (120 mg), Cohort 2 (240 mg), and Cohort 3 (360 mg). If safety and tolerability are deemed acceptable in a given cohort, enrollment proceeds sequentially to the next higher dose level.

02

Conditions studied

  • CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
03

In context

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

This study's enrollment of 9 is below the median of 39 across 84 interventional studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Lead sponsor

Kine Sciences Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥19 years at .
  • Diagnosed with CIDP and to treatment for ≥3 months prior to enrollment, or corticosteroid treatment deemed inappropriate or cannot be continued for safety reasons.
  • Meets EAN/PNS 2021 criteria for typical CIDP:

    • Progressive or relapsing symmetrical motor weakness in arms and legs with sensory involvement in ≥2 limbs
    • Symptom duration ≥8 weeks
    • Reduced or absent tendon reflexes in all extremities
  • INCAT disability score ≥2 at screening (score of 2 must result solely from leg disability).
  • CIDP Disease Activity Status (CDAS) score ≥3 at screening.
  • Received IVIg ≥2 months prior to IP administration.
  • If the subject is of , agrees to use highly effective for ≥28 days after IP administration.
  • Adequate venous access for IV administration and blood sampling.
  • Willing and able to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Polyneuropathy due to other causes (e.g., MMN, MGUS with anti-MAG antibodies, hereditary neuropathies, POEMS syndrome, diabetic or systemic disease-related neuropathy, drug/toxin-induced neuropathy).
  • History of myelopathy or confirmed central demyelination.
  • Known allergy or to the product or its .
  • Uncontrolled severe hepatic disease, CNS disorders, alcoholism, substance abuse, or psychiatric disorders.
  • Other medical conditions that better explain symptoms (e.g., stroke, CNS trauma, connective tissue disease).
  • within 5 years, except adequately treated low-risk cancers.
  • Moderate to severe heart failure or severe cardiovascular disease (e.g., MI, ischemic stroke).
  • Moderate to severe substance or alcohol use disorder within 1 year.
  • Positive pregnancy test or planning pregnancy, breastfeeding, or gamete donation within 28 days post-IP.
  • Use of systemic or immunostimulants within 5 half-lives prior to IP administration.
  • Plasma exchange within 8 weeks prior to IP administration.
  • Chronic infections or expected need for anti-infective treatment during the study.
  • Active or C infection or positive.
  • Abnormal labs at screening: /ALT >3×, \<9 g/dL, ANC \<1,500/μL, \<100×10³/μL.
  • Major surgery within 3 months or planned during study participation.
  • Investigator deems subject unsuitable for any reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    KINE-101 120mg

    Subjects received a single intravenous dose of KINE-101 120 mg.

    Drug: KINE-101

  • Experimental
    KINE-101 240 mg

    Subjects received a single intravenous dose of KINE-101 240 mg.

    Drug: KINE-101

  • Experimental
    KINE-101 360 mg

    Subjects received a single intravenous dose of KINE-101 360 mg.

    Drug: KINE-101

Interventions

  • KINE-101 injection, 12.5 mg/mL, administered once intravenously on Day 1.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Incidence, severity, and relationship of treatment-emergent adverse events following a single intravenous dose of KINE-101.

    Time frame: Day 1 to Day 28

  2. Number of Participants with Clinically Significant Abnormal Hematology

    Count of participants with clinically significant abnormal hematology findings (e.g., white blood cell count, hemoglobin, platelets, absolute neutrophil count), as defined per protocol.

    Time frame: Day 1 to Day 28

  3. Number of Participants with Clinically Significant Abnormal Clinical Chemistry

    Count of participants with clinically significant abnormal clinical chemistry findings (e.g., ALT, AST, creatinine), as defined per protocol.

    Time frame: Day 1 to Day 28

  4. Number of Participants with Clinically Significant Abnormal Urinalysis

    Count of participants with clinically significant abnormal urinalysis findings (e.g., protein/albumin, glucose, pH), as defined per protocol.

    Time frame: Day 1 to Day 28

  5. Number of Participants with Clinically Significant Abnormal Vital Signs

    Count of participants with clinically significant abnormal vital sign findings (e.g., systolic or diastolic blood pressure, pulse rate, body temperature, respiratory rate), as defined per protocol.

    Time frame: Day 1 to Day 28

  6. Number of Participants with Clinically Significant Abnormal Physical Examination

    Count of participants with clinically significant abnormal physical examination findings, as defined per protocol.

    Time frame: Day 1 to Day 28

  7. Number of Participants with Clinically Significant Abnormal Electrocardiogram

    Count of participants with clinically significant abnormal electrocardiogram findings (e.g., PR interval, QRS duration, QT interval), as defined per protocol.

    Time frame: Day 1 to Day 28

Other outcomes

  1. Change From Baseline in Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Change from baseline in the INCAT disability score (range 0-10; higher scores indicate worse disability).

    Time frame: Day 1 (predose), Day 14, and Day 28

  2. Change From Baseline in Medical Research Council (MRC) Sum Score

    Change from baseline in the MRC sum score (range 0-60; higher scores indicate better muscle strength).

    Time frame: Day 1 (predose), Day 14, and Day 28

  3. Change From Baseline in Inflammatory Rasch-Built Overall Disability Scale (I-RODS)

    Change from baseline in the I-RODS score (range 0-48; higher scores indicate better function).

    Time frame: Day 1 (predose), Day 14, and Day 28

  4. Change From Baseline in Timed Up-and-Go (TUG) Test

    Change from baseline in the Timed Up-and-Go test, measured in seconds (lower values indicate better performance).

    Time frame: Day 1 (predose), Day 14, and Day 28

  5. Change From Baseline in Mean Grip Strength

    Change from baseline in mean grip strength (higher values indicate greater muscle strength).

    Time frame: Day 1 (predose), Day 14, and Day 28

  6. Change From Baseline in Overall Neuropathy Limitations Scale (ONLS)

    Change from baseline in the ONLS score (range 0-12; higher scores indicate worse disability).

    Time frame: Day 1 (predose), Day 14, and Day 28

  7. Peak Plasma Concentration of KINE-101 (Cmax)

    Maximum observed plasma concentration of KINE-101.

    Time frame: Day 1

  8. Area Under the Plasma Concentration-Time Curve of KINE-101 (AUC)

    Area under the plasma concentration-time curve of KINE-101 (AUClast and AUCinf).

    Time frame: Day 1

  9. Change From Baseline in Immunophenotyping markers following KINE-101 administration

    The change from baseline in immunophenotyping markers following intravenous administration of KINE-101 including CD4, CD25, FoxP3, CD39, CD69, CTLA4, LAG-3, TNFR2, TIGIT, CCR5, and CXCR3.

    Time frame: Day 1 to Day 28

  10. Change From Baseline in Serum biomarkers following KINE-101 administration

    The change from baseline in serum biomarkers following intravenous administration of KINE-101 including IgG, IgM, IL-2, IL-6, IL-10, IL-17, IFN-gamma, MCP-1, and TGF-beta.

    Time frame: Day 1 to Day 28

  11. Changes From Baseline in Autoantibodies and Inflammatory Laboratory markers following KINE-101 administration

    Changes from baseline in serum autoantibodies and inflammatory laboratory markers.

    Time frame: Day 1 to Day 28

07

Study locations

2 sites
  • Kangbuk Samsung Hospital
    Seoul, Seoul 03181, South Korea
  • Samsung Medical Center
    Seoul, Seoul 06351, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Apr 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 15, 2026
StartActual
Aug 27, 2024
Primary completionActual
Apr 14, 2025
CompletionActual
Apr 14, 2025
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07343310
Lead sponsor
Kine Sciences Co., Ltd.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Aug 27, 2024
Primary completion
Apr 14, 2025
Completion
Apr 14, 2025
Last update
Jan 20, 2026

Study contacts

Hanna Park
study director · Kine Sciences Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KINE-101

Start the discussion